Close Menu

Tissue-Based Testing

News on immunohistochemistry and other tissue-based testing methods.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

The company reported on its development of a deep learning model to predict gene expression of tumors from whole slide images without the need to sequence RNA.

The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging. 

The company has developed a microscopy system that allows imaging of a full pathology slide in 21 channels with a single staining process and a rapid turnaround time.

Bio-Techne said pathologists now have access to its fully automated RNAscope technology, providing them with a new tool to evaluate disease biomarkers.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.